Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

NCT01922921 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

HER2/Neu Positive
Recurrent Breast Carcinoma
Stage IV Breast Cancer

Interventions

BIOLOGICAL: HER-2/neu Intracellular Domain Protein
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pertuzumab
OTHER: Placebo
BIOLOGICAL: Polysaccharide-K
BIOLOGICAL: Trastuzumab

Sponsor

University of Washington

Collaborators

[object Object]
[object Object]